Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Approves Once-Monthly Abilify For Schizophrenia, sold by Otsuka Holdings Co Ltd And H Lundbeck A/S-Reuters


Thursday, 28 Feb 2013 08:03pm EST 

Reuters reported that U.S. regulators has approved a once-monthly injectable form of Abilify which will be sold by Otsuka Holdings Co Ltd and H Lundbeck A/S. 

Company Quote

125.0
-1.0 -0.79%
11 Jul 2014